Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioids Stuck In Pipeline Should Not Wait For REMS, National Pain Foundation Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Products can be folded into new class-wide risk management plan once it is developed, foundation tells FDA public meeting.

You may also be interested in...



Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning

Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins

Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning

Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins

Opioid REMS Pilot Program Urged At Public Meeting

FDA wrestles with balancing the urgency of patient safety with the desire for a well designed risk management program for pain products.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel